NCT01546519View on ClinicalTrials.gov

A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Cancer
Interventions
DRUG

Vismodegib

oral repeating dose of 150 mg once daily

Trial Locations (5)

10017

New York

21201

Baltimore

48201

Detroit

60637

Chicago

03756

Lebanon

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY